Trial Information
Inclusion Criteria:
- patients 10 to 90 years old with primary or treatment-related MDS or chronic
myelomonocytic leukemia;
- International Prognostic Scoring System(IPSS) intermediate-1,intermediate-2,or high
risk;
- bone marrow blasts > 11% or <= 10% and poor cytogenetics;
- lack of an HLA-identical donor;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
- adequate cardiac and hepatorenal functions.
Exclusion Criteria:
- have an HLA-identical donor
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
complete remission
Outcome Time Frame:
six months
Safety Issue:
Yes
Principal Investigator
Sheng Hui Ai, M.D
Investigator Role:
Principal Investigator
Investigator Affiliation:
Affiliated Hospital of Academy of Military Medical Sciences
Authority:
China: Ethics Committee
Study ID:
MST/MDS-307PLAH-ASH
NCT ID:
NCT01674985
Start Date:
September 2009
Completion Date:
December 2013
Related Keywords:
- Myelodysplastic Syndromes
- Decitabine
- microtransplantation
- myelodysplastic syndromes
- chemotherapy
- Myelodysplastic Syndromes
- Preleukemia